Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol
Introduction The optimal dose and treatment modality of neoadjuvant radiotherapy applied for treating borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC) have been debated topics in oncology. The objective of the present network meta-analysis (NMA) is to study and comp...
Saved in:
Main Authors: | Xin Wang, Dan Cao, Qingfeng Wang, Qiancheng Hu, Wanrui Lv |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-07-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/7/e050558.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma
by: Kai Tai Derek Yeung, PhD, FRCS, et al.
Published: (2024-09-01) -
Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma
by: Yunzhen Qian, et al.
Published: (2022-01-01) -
Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma
by: Caroline Y. K. Fong, et al.
Published: (2019-01-01) -
Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
by: Heng‐Chung Kung, et al.
Published: (2023-04-01) -
Identification of key regulators in pancreatic ductal adenocarcinoma using network theoretical approach.
by: Kankana Bhattacharjee, et al.
Published: (2025-01-01)